iSage Health · Gut Health Research

What the Research Actually Says About Enterosgel

A look at the published clinical trials behind Enterosgel — how it performed against placebo for IBS-D and acute diarrhoea, how it works at a molecular level, and where the science is headed next.

Plenty of gut-health products make claims. Far fewer have been through a randomised, placebo-controlled trial. Enterosgel has been through several — including one of the largest trials ever run for IBS with diarrhoea (IBS-D). This article goes through what that research actually found, in plain terms, along with a look at where the science is headed next.

For the product specifics — dosage, composition, TGA registration — see the Enterosgel product page. This article is about the evidence behind it.

The IBS-D trial: 440 patients, eight weeks, one clear result

The most significant study is the RELIEVE-IBS-D trial, a double-blinded, randomised, placebo-controlled trial published in Gut in 2022 by Yiannakou and colleagues — one of the largest randomised trials ever conducted for IBS-D. 440 adults aged 16–75 were randomised to Enterosgel or placebo for an 8-week double-blind treatment phase, followed by an 8-week open-label phase.

"Enterosgel seems to be safe and effective in reducing the main symptoms in IBS-D" — including bloating, bowel urgency and abdominal pain, with an accompanying improvement in quality of life. Dr Yan Yiannakou, consultant neurogastroenterologist, University Hospital of North Durham

The acute diarrhoea trial: symptoms resolving roughly 12 hours sooner

A separate randomised controlled trial, led by Howell and Arasaradnam and published in BMJ Open Gastroenterology (2019), tested Enterosgel plus oral rehydration solution (ORS) against ORS alone in adults presenting to primary care with acute diarrhoea — 105 adults across 10 GP practices, 86 completing the trial.

64% of the Enterosgel group had resolved within 24 hours, vs 55% in the control group. NNT: 5. No serious adverse events were reported in the treatment group; one hospitalisation occurred in the control group. A roughly 12-hour reduction in diarrhoea duration sounds modest until you're the one dealing with it — particularly for people more vulnerable to dehydration, or who simply need to get back to work or caring for a family faster.

How it actually works: an adsorption study, not a marketing claim

The mechanism behind Enterosgel has also been tested directly. A laboratory study by Howell, Mikhalovsky, Markaryan and Khovanov, published in Scientific Reports (2019), measured how much of various bacterial toxins, bile acids and drugs Enterosgel could adsorb in vitro, benchmarked against activated charcoal.

• Enterosgel adsorbed a substantial proportion of the bacterial toxins tested — including Clostridium difficile Toxins A and B, and Shiga Toxin — though generally less than activated charcoal.
• Adsorption followed a second-order reaction pathway, consistent with a physical binding mechanism rather than a chemical or pharmacological one.
• The researchers noted this supports Enterosgel's proposed mechanism: binding target molecules in the gut and removing them from the body, rather than being absorbed itself.

This is also the basis for the standard advice to separate Enterosgel from other oral medications by at least two hours — the same non-selective binding that helps it adsorb toxins means it can adsorb other substances passing through the gut at the same time.

The health-system angle: shorter hospital stays

Beyond individual symptom relief, a cost-minimisation analysis by Ravasio and Raimondo, published in AboutOpen (2021), modelled the economic impact of adding Enterosgel to standard hospital care for non-infectious diarrhoea. Adding Enterosgel to standard care was associated with shorter hospital stays — modelled valorisation gains of roughly €68–€559 per patient, and a projected annual gain of around €82,600 for a 10-bed ward from increased bed turnover.

It's a hospital-system study rather than a consumer one, but it's a useful data point: the symptom benefits seen in the clinical trials translate into a measurable operational impact when applied at scale.

Where the research is headed next

Enterosgel's approved uses in Australia remain acute diarrhoea and IBS-D — but researchers are actively investigating other potential applications. Nurse researcher Symriti Kaur-Paneser, winner of Guts UK's 2025 Nurse Recognition Award for Improvement in Patient Care, is currently running an in-vitro study (backed by the Dr Falk Guts award) into whether Enterosgel can selectively bind cytokines and enzymes relevant to ulcerative colitis (UC) — specifically targeting faecal urgency, which Guts UK notes affects up to 50% of UC patients even when the disease itself is quiet.

The takeaway

Across a large randomised IBS-D trial, a primary-care diarrhoea trial, a mechanistic lab study and a health-economics analysis, the picture is consistent: Enterosgel measurably outperforms placebo on the symptoms it's registered to treat, its proposed binding mechanism holds up under laboratory testing, and it has a long safety track record with no systemic absorption. That's a reasonably unusual amount of published evidence for a product in this category.

Full usage directions, dosage and safety information are on the product page.

Shop Enterosgel — 225g Tube →

Questions before ordering? See our FAQ, Science & Research page, or contact us directly.
Looking for other options? Browse our Detox range or full product range.